The reduction from baseline in the number of days per week in which patients did not use cocaine was 13
The primary outcome measure was cocaine abstinence verified by twice weekly urine benzoylecgonine tests (UBT)
In this regard, as contingency management shows promise in the treatment of cocaine use disorder [8–10], it would be interesting to see how topiramate might perform in the context of an adherence-supporting contingency management intervention involving topiramate in comparison to placebo
ADJUNCTIVE THERAPY: 17 years or older: See Adult Dosing
It is possible that topiramate supported cocaine abstinence due to its anxiolytic properties
Mild topiramate side effects include a “pins and needles” feeling, weight loss, and dizziness
Evidence for topiramate in the treatment of cocaine dependence is promising, but limited by small sample size
Topiramate reduced alcohol craving and alcohol use in a group of 24 alcohol dependent
, respectively) of experimentally administered cocaine in 24 male and female, cocaine-dependent, non-treatment-seeking research volunteers in a Topiramate (TOP) is an antiepileptic drug that may have utility in the treatment of cocaine dependence because it enhances the GABAergic system, antagonizes the glutamatergic system, and has been identified by NIDA as one of only a few medications providing a "positive signal" warranting further clinical investigation
Two antipsychotics, risperidone (2 to 4 mg/d) and aripiprazole (15 mg/d), were studied and no difference in time to relapse Background